Collectively, activation of GATM may represent an efficient therapeutic approach for ccRCC harboring the PBRM1 mutation under ICIs by regulating creatine metabolism to enhance antitumor T cell immunity in the tumor microenvironment. This evidence concerns the gene PBRM1 and neoplasm.